StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.94 | $1.94 | +0.00% | 0.6M |
| 05-12 | $1.96 | $1.91 | -2.55% | 0.6M |
| 05-13 | $1.97 | $1.93 | -2.03% | 2.2M |
| 05-14 | $1.95 | $2.00 | +2.56% | 0.9M |
| 05-15 | $2.00 | $1.98 | -1.00% | 1.1M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Each factor shows PLX's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q3 2026 (Est.) Expected 2026-08-12 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $25.45M | $33.75M | $52.74M | $43.62M | $25.77M |
Operating Income | Not available | $21.15M | $-5.50M | $-842.00K | $-2.97M |
Net Income | Not available | $18.32M | $-6.60M | $-1.10M | $-3.46M |
EPS (Diluted) | $0.12 | $0.22 | $-0.08 | $-0.01 | $-0.04 |
Total Assets | Not available | $102.34M | $82.35M | $82.26M | $78.49M |
Total Liabilities | Not available | $35.11M | $34.12M | $29.36M | $28.58M |
Cash & Equivalents | Not available | $41.00M | $14.68M | $13.65M | $17.89M |
Free Cash Flow OCF − CapEx | Not available | $21.26M | $-13.63M | $-15.26M | $-11.03M |
Shares Outstanding | Not available | 83.05M | 80.43M | 78.23M | 77.65M |